Top

Published in:

Open Access 01-12-2017 | Research

Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease

Authors: Virginia Albiñana, Rosa María Jiménez Escribano, Isabel Soler, Luis Rodríguez Padial, Lucia Recio-Poveda, Karina Villar Gómez de las Heras, Luisa María Botella

Published in: Orphanet Journal of Rare Diseases | Issue 1/2017

Abstract

Background

Von Hippel-Lindau (VHL) disease is a rare oncological disease with an incidence of 1:36,000, and is characterized by the growth of different types of tumours. Haemangioblastomas in the central nervous system (CNS) and retina, renal carcinoma and pheochromocytomas are the most common tumours. The absence of treatment for VHL leads to the need of repeated surgeries as the only option for these patients. Targeting VHL-derived tumours with drugs with reduced side effects is urgent to avoid repeated CNS surgeries. Recent reports have demonstrated that propranolol, a β-blocker used for the treatment of hypertension and other cardiac and neurological diseases, is the best option for infantile hemangioma (IH). Propranolol could be an efficient treatment to control haemangioblastoma growth in VHL disease given its antiangiogenic effects that were recently demonstrated by us. The main objective of the present study was the assessment of the efficacy and safety of propranolol on retinal haemangioblastoma in von Hippel-Lindau disease (VHL).

Methods

7 VHL patients, from different regions of Spain, affected from juxtapapillary or peripheral haemangioblastomas were administered 120 mg propranolol daily. Patients were evaluated every 3 months for 12 months, at Virgen de la Salud Hospital (Toledo). The patients had juxtapapillary or peripheral haemangioblastomas but had refused standard treatments.

Results

Propranolol was initiated with a progressive increase up to a final dose of 120 mg daily. All tumours remained stable, and no new tumours appeared. The reabsorption of retinal exudation was noted in the two patients having exudates. No adverse effects were recorded. VEGF and miRNA 210 levels were monitored in the plasma of patients as possible biomarkers of VHL. These levels decreased in all cases from the first month of treatment.

Conclusions

Although more studies are necessary, the results of this work suggest that propranolol is a drug to be considered in the treatment of VHL patients with retinal haemangioblastomas. VEGF and miRNA 210 could be used as biomarkers of the VHL disease activity.

Trial registration

The study has a clinical trial design and was registered at EU Clinical Trials Register and Spanish Clinical Studies Registry, EudraCT Number: 2014–003671-30. Registered 2 September 2014.

Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, et al. Clinical Features and Natural History of von Hippel-Lindau Disease. Q J Med. 1990;283:1151–63.CrossRef

Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. Von Hippel-Lindau disease. Lancet. 2003:2059–67.

González Escobar AB, Morillo Sánchez MJ, García-Campos JM. Enfermedad de Von Hippel Lindau: estudio familiar. Arch Soc Esp Oftalmol. 2012;87(11):368–72.CrossRefPubMed

Richard S, Gardie B, Couvè S, Von Hippel-Lindau GS. How a rare disease illuminates cancer biology. Semin Cancer Biol. 2013;23:26–37.CrossRefPubMed

Chan CC, Collins ABDCE. molecular pathology of eyes with von hippel–lindau (vhl) disease a review. Retina. 2007;27(1):1–7.CrossRefPubMedPubMedCentral

Maher ER, Neumann HP, Richard S. von Hippel–Lindau disease: A clinical and scientific review. Eur J Hum Genet. 2011;19(6):617–23. Available from: http://www.nature.com/ejhg/journal/v19/n6/full/ejhg2010175a.

Chew EY. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans Am Ophthalmol Soc. 2005;103:495–511. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1447586&tool=pmcentrez&rendertype=abstract.

Papastefanou V, Pilli S, Stinghe A, Lotery AJ, Cohen V. Photodynamic therapy for retinal capillary hemangioma. Eye. 2013;27:438–42. doi:10.1038/eye.2012.259.CrossRefPubMedPubMedCentral

Chen Y, Liu H, Zhang K, Gao L. Massive exudative retinal detachment following photodynamic therapy for retinal hemangioma in von Hippel-Lindau Syndrome. Photodiagn Photodyn Ther. 2014;11(2):250–3.CrossRef

10.

Tsai F-Y, Lau L-I, Chen S-J, Lee F-L, Lee S-M. Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel-Lindau disease. J Chin Med Assoc. 2014 Jan 1 [cited 2017 Feb 5];77(1):52–6. Available from: http://www.jcma-online.com/article/S172649011300244X/fulltext.

11.

Hussain RN, Jmor F, Damato B, Heimann H. Verteporfin photodynamic therapy for the treatment of sporadic retinal capillary haemangioblastoma. Photodiagn Photodyn Ther. 2015;12(4):555–60.CrossRef

12.

HM K, KH P. Massive Exudative Retinal Detachment Following Photodynamic Therapy and Intravitreal Bevacizumab Injection in Retinal Capillary Hemangioma. Indian J Dermatol Venereol Leprol. 2009;75(3):225–8. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9917727.CrossRef

13.

von Buelow M, Pape S, Hoerauf H. Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. Acta Ophthalmol Scand. 2007;85(1):114–6.CrossRef

14.

Wackernagel W, Lackner E-M, Pilz S, Mayer C, Stepan V. von Hippel-Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumab. Acta Ophthalmol. 2010;88:e271–2.CrossRefPubMed

15.

Slim E, Antoun J, Kourie HR, Schakkal A, Cherfan G. Intravitreal bevacizumab for retinal capillary haemangioblastoma: A case series and literature review. Can J Ophthalmol. 2014;49(5):450–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25284102.CrossRefPubMed

16.

Wong WT, Liang KJ, Hammel K, Coleman HR, Chew EY. Intravitreal ranibizumab therapy for retinal capillary haemangioblastoma related to von Hippel-Lindau disease. Ophthalmology. 2008 Nov 1 [cited 2017 Feb 5];115(11):1957–64. Available from: http://www.aaojournal.org/article/S0161642008004211/fulltext.

17.

Wang Y, Abu-Asab MS, Shen D, Zhuang Z, Chew EY, Chan CC. Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal haemangioblastoma. Graefes Arch Clin Exp Ophthalmol. 2014;252(8):1319–27.CrossRefPubMed

18.

Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: Insights into the molecular mechanisms of action. Br J Dermatol. 2010;163:269–74.CrossRefPubMed

19.

Greenberger S, Bischoff J. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb Perspect Med. 2011;1(1):a006460.CrossRefPubMedPubMedCentral

20.

Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J-B, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358(24):2649–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20117846.

21.

Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628–38. Available from: www.impactjournals.com/oncotarget.

22.

Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809. Available from: www.impactjournals.com/oncotarget CrossRefPubMedPubMedCentral

23.

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol. 2011;

24.

Ganz PA, Habel LA, Weltzien EK, Caan BJCS. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: Results from the LACE cohort. Breast Cancer Res Treat. 2012;129(2):549–56.CrossRef

25.

Peridis S, Pilgrim G, Athanasopoulos I, Parpounas K. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol. 2011;75:455–60.CrossRefPubMed

26.

Hernandez-Martin S, Lopez-Gutierrez JC, Lopez-Fernandez S, Ramrez M, Miguel M, Coya J, et al. Brain perfusion SPECT in patients with PHACES syndrome under propranolol treatment. Eur J Pediatr Surg. 2012;22:54–9.CrossRefPubMed

27.

Alexiou GA, Moschovi M, Prodromou N. Letter to the Editor: Pediatric cavernomas. J Neurosurg Pediatr 2012;10(3):252. Available from: doi: 10.3171/2011.12.PEDS11503

28.

Berti I, Marchetti F, Skabar A, Zennaro F, Zanon DVA. Propranolol for cerebral cavernous angiomatosis: A magic bullet. Clin Pediatr (Phila). 2014;53(2):189–90.CrossRef

29.

Zabramski JM, Kalani MYS, Filippidis AS, Spetzler RF. Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. World Neurosurg. 2016;88:631–9.CrossRefPubMed

30.

Thapa R, Shields CL. Oral propranolol therapy for management of exudative retinal detachment from diffuse choroidal hemangioma in Sturge-Weber syndrome. Eur J Ophthalmol. 2013;23(6):922–4.CrossRefPubMed

31.

Léauté-Labrèze C. Le propranolol dans les hémangiomes. Arch Pédiatrie. 2012;19:H113–4.CrossRef

32.

Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for Severe Infantile Hemangiomas: Follow-Up Report. Pediatrics. 2009;124(3):e423–31. Available from: http://www.pediatrics.aappublications.org/content/124/3/e423.CrossRefPubMed

33.

Lamy S, Lachambre MP, Lord-Dufour S, Beliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vasc Pharmacol. 2010;53(5–6):200–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20732454.CrossRef

34.

Albiñana V, Recio-Poveda L, Zarrabeitia R, Bernabéu C, Botella LM. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thromb Haemost. 2012;108(1):41–53.CrossRefPubMed

35.

Albiñana V, Villar Gómez de Las Heras K, Serrano-Heras G, Segura T, Perona-Moratalla AB, Mota-Pérez M, et al. Propranolol reduces viability and induces apoptosis in haemangioblastoma cells from von Hippel-Lindau patients. Orphanet J Rare Dis. 2015;10(1):118. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26394686%5C, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4579575.

36.

Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang Y, et al. MicroRNA-210 is upregulated by hypoxia-inducible factor-1alpha in the stromal cells of giant cell tumours of bone. Mol Med Rep. 2015;12(4):6185–92.PubMed

37.

Wizigmann-Voos S, Plate KH. Pathology, genetics and cell biology of haemangioblastomas. Histol Histopathol. 1996;11:1049–61.PubMed

38.

Frolov VA, Moiseeva EG. Pasechnik AV, Pathophysiological aspects of functional modulation of human peripheral blood neutrophils with propranolol. Bull Exp Biol Med. 2006;(6):141, 675–7.

39.

Munabi NCO, England RW, Edwards AK, Kitajewski AA, Tan QK, Weinstein A, et al. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. Stem Cells Transl Med. 2016;5(1):45–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26574555%5C, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4704871.

Title: Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease
Authors: Virginia Albiñana
Rosa María Jiménez Escribano
Isabel Soler
Luis Rodríguez Padial
Lucia Recio-Poveda
Karina Villar Gómez de las Heras
Luisa María Botella
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2017
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-017-0664-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease

Abstract

Background

Methods

Results

Conclusions

Trial registration

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2017

ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T

Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery

Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex

Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness

Expanding the clinical and mutational spectrum of B4GALT7-spondylodysplastic Ehlers-Danlos syndrome

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease